Oncothyreon's closing of $46M offering will aid early cancer candidates
This article was originally published in Scrip
Oncothyreon, a clinical-stage biopharmaceutical company focusing on treatments for cancers, has closed on its latest equity offering of 11.5 million shares of common stock at a price of $4 per share. Underwriters were Cowen & Co and Wedbush PacGrow Life Sciences. As an over-allotment was exercised, the firm has estimated net proceeds are about $43 million.